Use of rituximab in lymphomatoid granulomatosis with isolated central nervous system involvement

Jesse Mooneyham; Cesar Gentille; Andrea Barbieri; Shilpan Shah

doi:10.1136/bcr-2020-235412

Use of rituximab in lymphomatoid granulomatosis with isolated central nervous system involvement

Jesse Mooneyham, Cesar Gentille, Andrea Barbieri, Shilpan Shah

Houston Methodist

Research output: Contribution to journal › Article › peer-review

Abstract

A 33-year-old woman presented to the emergency room with severe headaches. A CT scan of the head revealed two brain lesions with associated vasogenic oedema. Diagnostic resection of one of the lesions followed by pathological analysis revealed grade III lymphomatoid granulomatosis (LYG). Staging investigations elsewhere in the body were negative, isolating this case of LYG to the central nervous system, an atypical presentation. After the resection, she was treated with single-agent rituximab 375 mg/m 2. The follow-up MRI demonstrated the resolution of brain lesions and no progression of the disease.

Original language	English (US)
Article number	235412
Journal	BMJ Case Reports
Volume	13
Issue number	9
DOIs	https://doi.org/10.1136/bcr-2020-235412
State	Published - Sep 7 2020

Keywords

haematology (drugs and medicines)
malignant and benign haematology
malignant disease and immunosuppression
neurooncology
neurosurgery

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1136/bcr-2020-235412

Cite this

@article{2724893d157a40ecafd389a33f74a5b5,

title = "Use of rituximab in lymphomatoid granulomatosis with isolated central nervous system involvement",

abstract = "A 33-year-old woman presented to the emergency room with severe headaches. A CT scan of the head revealed two brain lesions with associated vasogenic oedema. Diagnostic resection of one of the lesions followed by pathological analysis revealed grade III lymphomatoid granulomatosis (LYG). Staging investigations elsewhere in the body were negative, isolating this case of LYG to the central nervous system, an atypical presentation. After the resection, she was treated with single-agent rituximab 375 mg/m 2. The follow-up MRI demonstrated the resolution of brain lesions and no progression of the disease.",

keywords = "haematology (drugs and medicines), malignant and benign haematology, malignant disease and immunosuppression, neurooncology, neurosurgery",

author = "Jesse Mooneyham and Cesar Gentille and Andrea Barbieri and Shilpan Shah",

note = "Publisher Copyright: {\textcopyright} BMJ Publishing Group Limited 2020.",

year = "2020",

month = sep,

day = "7",

doi = "10.1136/bcr-2020-235412",

language = "English (US)",

volume = "13",

journal = "BMJ Case Reports",

issn = "1757-790X",

publisher = "BMJ Publishing Group",

number = "9",

}

TY - JOUR

T1 - Use of rituximab in lymphomatoid granulomatosis with isolated central nervous system involvement

AU - Mooneyham, Jesse

AU - Gentille, Cesar

AU - Barbieri, Andrea

AU - Shah, Shilpan

N1 - Publisher Copyright: © BMJ Publishing Group Limited 2020.

PY - 2020/9/7

Y1 - 2020/9/7

N2 - A 33-year-old woman presented to the emergency room with severe headaches. A CT scan of the head revealed two brain lesions with associated vasogenic oedema. Diagnostic resection of one of the lesions followed by pathological analysis revealed grade III lymphomatoid granulomatosis (LYG). Staging investigations elsewhere in the body were negative, isolating this case of LYG to the central nervous system, an atypical presentation. After the resection, she was treated with single-agent rituximab 375 mg/m 2. The follow-up MRI demonstrated the resolution of brain lesions and no progression of the disease.

AB - A 33-year-old woman presented to the emergency room with severe headaches. A CT scan of the head revealed two brain lesions with associated vasogenic oedema. Diagnostic resection of one of the lesions followed by pathological analysis revealed grade III lymphomatoid granulomatosis (LYG). Staging investigations elsewhere in the body were negative, isolating this case of LYG to the central nervous system, an atypical presentation. After the resection, she was treated with single-agent rituximab 375 mg/m 2. The follow-up MRI demonstrated the resolution of brain lesions and no progression of the disease.

KW - haematology (drugs and medicines)

KW - malignant and benign haematology

KW - malignant disease and immunosuppression

KW - neurooncology

KW - neurosurgery

UR - http://www.scopus.com/inward/record.url?scp=85090975808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090975808&partnerID=8YFLogxK

U2 - 10.1136/bcr-2020-235412

DO - 10.1136/bcr-2020-235412

M3 - Article

C2 - 32900727

AN - SCOPUS:85090975808

SN - 1757-790X

VL - 13

JO - BMJ Case Reports

JF - BMJ Case Reports

IS - 9

M1 - 235412

ER -

Use of rituximab in lymphomatoid granulomatosis with isolated central nervous system involvement

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this